SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): A multi-center, retrospective, observational study

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Yoo, Byung Su ^a   Oh, Jaewon ^b   Hong, Bum Kee ^c   Shin, Dae Hee ^d   Bae, Jang Ho ^e   Yang, Dong Heon ^f   Shim, Wan Joo ^g   Kim, Hyung Seop ^h   Kim, Su Hong ⁱ   Choi, Jin Oh ^j   Chun, Woo Jung ^k   Go, Choong Won ^l   Kang, Hyun Jae ^m   Baek, Sang Hong ⁿ   Cho, Jang Hyun ^o   Hong, Suk Keun ^p   Shin, Joon Han ^q   Oh, Seok Kyu ^r   Pyun, Wook Bum ^s   Kwan, Jun ^t   Hong, Young Joon ^u   Jeong, Jin Ok ^v   Kang, Seok Min ^b   Choi, Dong Ju ^w   more..

^a Yonsei University Wonju   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Gangneung Asan Hospital   (South Korea)

^e Konyang University College of Medicine   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h Keimyung University   (South Korea)

ⁱ Busan Veterans Hospital   (South Korea)

^j Samsung Medical Center   (South Korea)

^k Sungkyunkwan University School of Medicine   (South Korea)

^l Inje University College of Medicine   (South Korea)

^m Seoul National University Hospital   (South Korea)

ⁿ The Catholic University of Korea   (South Korea)

^o Saint Carollo Hospital   (South Korea)

^p Sejong General Hospital   (South Korea)

^q Ajou University Medical Center   (South Korea)

^r Wonkwang University Hospital   (South Korea)

^s Mokdong Hospital   (South Korea)

^t Inha University Hospital   (South Korea)

^u Chonnam National University Medical School   (South Korea)

^v Chungnam National University College of Medicine   (South Korea)

^w Seoul National University Bundang Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; PERINDOPRIL; RAMIPRIL; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HEART EJECTION FRACTION; HOSPITALIZATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERFORMANCE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SURVIVAL; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DATA COLLECTION; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MEDICATION ADHERENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 84899921720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086596     Document Type: Article

References (32)

1. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, et al. (2005) Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 26: 1653-1659. (Pubitemid 41389697)
2. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, et al. (2007) Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297: 61-70. (Pubitemid 46041727)
3. Bonow RO, Ganiats TG, Beam CT, Blake K, Casey DE Jr, et al. (2012) ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation 125: 2382-2401.
4. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119: 1977-2016.
5. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847.
6. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, et al. (2004) National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 110: 724-731. (Pubitemid 39056273)
7. Fonarow GC (2011) Improving quality of care and outcomes for heart failure. -Role of registries. Circ J 75: 1783-1790.
8. Rohde LE, Goldraich L, Polanczyk CA, Borges AP, Biolo A, et al. (2006) A simple clinically based predictive rule for heart failure in-hospital mortality. J Card Fail 12: 587-593. (Pubitemid 44540258)
9. Alsheikh-Ali AA, Al-Mallah MH, Al-Mahmeed W, Albustani N, Al Suwaidi J, et al. (2009) Heart failure in patients hospitalized with acute coronary syndromes: observations from the Gulf Registry of Acute Coronary Events (Gulf RACE). Eur J Heart Fail 11: 1135-1142.
10. Atherton JJ, Hayward CS, Wan Ahmad WA, Kwok B, Jorge J, et al. (2012) Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 18: 82-88.
11. Stork S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, et al. (2008) Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study. Eur J Heart Fail 10: 1236-1245.
12. Peters-Klimm F, Muller-Tasch T, Schellberg D, Remppis A, Barth A, et al. (2008) Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy. Clin Res Cardiol 97: 244-252. (Pubitemid 351464525)
13. Zugck C, Franke J, Gelbrich G, Frankenstein L, Scheffold T, et al. (2012) Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol 101: 263-272.
14. Gjesing A, Schou M, Torp-Pedersen C, Kober L, Gustafsson F, et al. (2013) Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care. Eur J Heart Fail.
15. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, et al. (2009) Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 73: 1893-1900.
16. Tsuchihashi-Makaya M, Furumoto T, Kinugawa S, Hamaguchi S, Goto K, et al. (2010) Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Hypertens Res 33: 197-202.
17. Youn YJ, Yoo BS, Lee JW, Kim JY, Han SW, et al. (2012) Treatment Performance Measures Affect Clinical Outcomes in Patients With Acute Systolic Heart Failure. Circ J 76: 1151-1158.
18. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, et al. (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21.
19. Lund LH, Svennblad B, Melhus H, Hallberg P, Dahlstrom U, et al. (2013) Association of Spironolactone Use with All-Cause Mortality in Heart Failure: A Propensity Scored Cohort Study. Circ Heart Fail.
20. Lenzen MJ, Scholte op Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, et al. (2004) Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 25: 1214-1220.
21. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC (2006) Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 47: 76-84. (Pubitemid 43005168)
22. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, et al. (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27: 2725-2736. (Pubitemid 44729876)
23. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, et al. (2007) Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50: 768-777. (Pubitemid 47243795)
24. Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, et al. (2011) Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry. Korean Circ J 41: 363-371.
25. Oh C, Chang HJ, Sung JM, Kim JY, Yang W, et al. (2012) Prognostic Estimation of Advanced Heart Failure With Low Left Ventricular Ejection Fraction and Wide QRS Interval. Korean Circ J 42: 659-667.
26. Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, et al. (2012) Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF. J Am Heart Assoc 1: 16-26.
27. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717. (Pubitemid 29407370)
28. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551. (Pubitemid 39025171)
29. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, et al. (2012) Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308: 2097-2107.
30. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, et al. (2010) Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure. Am Heart J 160: 915-921.
31. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, et al. (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33: 2782-2795.
32. Kim JY, Kim HJ, Jung SY, Kim KI, Song HJ, et al. (2012) Utilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database. BMC Cardiovasc Disord 12: 60.